Drug intelligence / Profile preview

ReGenerCell

Development stage: Unknown
Lead developer: Avita Medical
Modality: Cell Therapies
Administration: Topical

Overview

ReGenerCell is an autologous cell harvesting medical device developed by Avita Medical for the treatment of chronic wounds, including venous leg ulcers and diabetic foot ulcers. The device enables clinicians to rapidly prepare a Regenerative Epithelial Suspension (RES) at the point of care using a small sample of the patient's own skin. This suspension contains a multi-phenotype population of cells, including keratinocytes, fibroblasts, and melanocytes, along with essential wound-healing factors that promote natural skin regeneration and healing in unresponsive wounds. ReGenerCell is CE-marked in Europe and has demonstrated statistically significant improvements in wound healing and patient quality of life in clinical trials.

Brand names: ReGenerCell
Other names: REGENERCELL Autologous Cell Harvesting Device

Beyond the preview

Go deeper on ReGenerCell.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ReGenerCell.

Explore the full profile